| Literature DB >> 22566960 |
Laura Oliveira-Nascimento1, Paola Massari, Lee M Wetzler.
Abstract
Toll-like receptors (TLRs) are recognition molecules for multiple pathogens, including bacteria, viruses, fungi, and parasites. TLR2 forms heterodimers with TLR1 and TLR6, which is the initial step in a cascade of events leading to significant innate immune responses, development of adaptive immunity to pathogens and protection from immune sequelae related to infection with these pathogens. This review will discuss the current status of TLR2 mediated immune responses by recognition of pathogen-associated molecular patterns (PAMPS) on these organisms. We will emphasize both canonical and non-canonical responses to TLR2 ligands with emphasis on whether the inflammation induced by these responses contributes to the disease state or to protection from diseases.Entities:
Keywords: TLR1; TLR2; TLR2 ligands; TLR6; co-receptors; polymorphisms
Year: 2012 PMID: 22566960 PMCID: PMC3342043 DOI: 10.3389/fimmu.2012.00079
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
TLR2 microbial ligands.
| Ligand | Origin | TLRS | Ligand delivery | Reference |
|---|---|---|---|---|
| Diacyl lipopeptides (MALP-2/FSL-1) | TLR2/TLR6 | RP105 (B cells)/CD14/CD36 | Jimenez-Dalmaroni et al. ( | |
| Heat-labile enterotoxins (b subunit) | TLR2/TLR1 | CD14/GD1a | Liang et al. ( | |
| Lipomannan/lipoarabinomannan | TLR2/TLR1 | CD14/CD36 | Jimenez-Dalmaroni et al. ( | |
| Lipoprotein | TLR2/? | CD14/CD36/RP105 | Jimenez-Dalmaroni et al. ( | |
| Lipoteichoic acid (LTA) | Gram-positive bacteria | TLR2/TLR6 | CD14/CD36/MBL | Jimenez-Dalmaroni et al. ( |
| Peptidoglycan (PG) | TLR2/? | CD14 | Natsuka et al. ( | |
| Porins | TLR2/TLR1 | Unknown | Massari et al. ( | |
| Triacyl lipopeptides (LPs) | Bacteria | TLR2/TLR1 | CD14/vitronectin + integrin β3 | Beutler et al. ( |
| Glucuronoxylomannan | TLR2/TLR1–TLR2/TLR6 | CD14/not dectin-1 | Fonseca et al. ( | |
| Phospholipomannan | TLR2/TLR6 | CD14/dectin-1 | Jouault et al. ( | |
| Unknown | TLR2/? | Dectin-1 | Bonfim et al. ( | |
| Unknown | TLR2/? | Dectin-1 | Nakamura et al. ( | |
| Unknown | TLR2/? | Dectin-1 | ||
| Yeast phase-specific protein (Yps3p) | TLR2/? | Dectin-1 | Aravalli et al. ( | |
| Zymosan | TLR2/TLR6 | CD14/dectin-1 | Ikeda et al. ( | |
| Glycosylphosphatidylinositol (GPI) anchors | TLR2/TLR1 | CD36/(likely) CD14 | Jimenez-Dalmaroni et al. ( | |
| Lipopeptidophosphoglycan | TLR2/TLR6 and TLR4 | Wong-Baeza et al. ( | ||
| lipophosphoglycan | TLR2/? | Kavoosi et al. ( | ||
| Lysophosphatidylserine | TLR2/? | van Riet et al. ( | ||
| EBV-encoded dUTPase | Epstein–Barr | TLR2/? | Not CD14 | Ariza et al. ( |
| Glycoprotein B | Cytomegalovirus | TLR2/TLR6 | CD14 | Barbalat et al. ( |
| Hepatitis B capsid | Hepatitis B | TLR2/? | CD14 | Cooper et al. ( |
| hepatitis C core and NS3 protein | Hepatitis C | TLR2/TLR6 | Unknown | Chang et al. ( |
| Unknown | Measles | TLR2/TLR6 | Unknown | Klouwenberg et al. ( |
| Unknown | Herpes simplex (1/2) | TLR2/TLR6 | Unknown | Klouwenberg et al. ( |
| Unknown | Vaccinia | TLR2/? | Unknown | Barbalat et al. ( |
| Unknown | Lymphocytic choriomeningitis | TLR2/? | CD14 | Zhou et al. ( |
| Unknown | Yellow fever | TLR2/? | Unknown | Querec et al. ( |
| Unknown | Varicella zoster | TLR2/? | CD14 | Wang et al. ( |
| Unknown | Respiratory syncytial | TLR2/TLR6 | Unknown | Klouwenberg et al. ( |
Observation: The question marks “?” presented in the table imply that the co TLR, required for TLR2 ligand recognition, is still undefined.
*Synthetic PGs does not induce TLR2 signaling, and TLR2 activation promoted by the natural ones was attributed to lipopeptide contamination by some authors (Travassos et al., .
**Zymosan activation through TLR2 was also attributed to contamination by other authors (Ikeda et al., .
***Dectin-1 recognizes β-glucans from histoplasma, but these molecules are normally shielded by α-glucans in this pathogen (Rappleye et al., .
****Intact GPI are recognized mainly by TLR2/TLR1, but exclusion of its .
*****The purity of this preparation is controversial (Vanlandschoot et al., .
Figure 1TLR2 signaling. After ligand recognition and consequent TLR2 dimer rearrangement, the TIR domain of TIRAP binds the TIR domain of TLR2 and recruits the adaptor protein MyD88. IRAKs are then recruited and IRAK 4 phosphorylates (P) IRAK1, which then initiates auto-phosphorylation. Phosphorylated IRAK1 dissociates from the complex and activates TRAF6. Since IRAK1 is rapidly degraded, IRAK2 also activates TRAF 6 in latter responses. Ubiquitinated (U) TRAF6 triggers the activation sequence TAB2 – TAK1 – IKK complex. IκB phosphorylation and ubiquitination by the IKK complex leads to its degradation and release of NF-κB translocation to the nucleus for gene up-regulation. TAK1 also activates MKK6 for subsequent JNK and p38 activation, leading to AP-1 activation that triggers gene transcription of cytokines and accessory molecules. Internalized receptor complex triggered by a viral ligand can activate by an unknown pathway IRF7/3 to IFN-β gene up-regulation or IRF2/IRF1/STAT1 for IFN-α gene up-regulation (Underhill et al., 1999; Watters et al., 2007; Liljeroos et al., 2008; Barbalat et al., 2009; Dietrich et al., 2010; Dunne et al., 2010). MyD88, myeloid differentiation primary-response gene 88; TIRAP, TIR adaptor protein; IRAK, interleukin-1 receptor associated kinase; TRAF, TNF receptor associated factor; TAK, transforming growth factor beta-activated kinase 1; TAB, TAK1-binding protein; MKK/JNK/P38, MAP kinases, NEMO/IKKs, kinase complex; NF-κB, nuclear factor-κB; IκB, kinase complex; AP, activator protein; IRF, interferon regulatory factor, STAT, signal transducer and activator of transcription 1.